Publication Date 01/04/2014         Volume. 6 No. 3   
Information to Pharmacists


From the desk of the editor

Business is tight!
Cash flow has evaporated!
The PGA calls for unity while simultaneously dismembering the business of consultant pharmacists.
The federal government continues to strip massive funds from the PBS to the extent that it is gasping for air.
Oh, and I forgot, the Revive Clinic thinks that pharmacists cannot vaccinate patients in community pharmacies ( It is actually a warehouse pharmacy group trying to destabilise the market here to push fellow-pharmacists off balance by supporting the Revive group).
Even wage-earning pharmacists have discovered that they have not had a rise in their pay over the past five years

read more
open full screen

Recent Comments

Click here to read...

Major NIH grant to strike down superbugs

Staff Writer

articles by this author...

Editing and Researching news and stories about global and local Pharmacy Issues

Professor Roger Nation, Dr Kade Roberts, Dr Tony Velkov and Associate Professor Jian Li. Associate Professor Phil Thompson is also part of the MIPS research team.
Doctors treating infectious disease who are down to the last line of defence against antibiotic-resistant superbugs will be buoyed by an A$4.48 million investment in designing new treatments and therapies.
Awarded by the National Institutes of Health (NIH) in the US, the grant will support researchers from the Monash Institute of Pharmaceutical Sciences (MIPS) and Rempex Pharmaceuticals in California to design and develop new antibiotics that are effective against bacterial ‘superbugs’ that cause life-threatening infections and are resistant to all current antibiotics.


The NIH has been a major funder of this innovative research program as this new grant is the third, large RO1 grant received over the last five years.

Antibiotic resistance is an urgent global medical challenge. Currently, a class of antibiotics known as polymyxins are used to treat multidrug-resistant bacteria. However infections that are unresponsive to this last-line therapy have recently been reported in many countries.

The MIPS team comprises Associate Professor Jian Li, Dr Tony Velkov, Professor Roger Nation, Associate Professor Philip Thompson and Dr Kade Roberts. Associate Professor Li and Professor Nation have been investigating polymyxins for more than a decade and are regarded as international leaders in the field.

Rempex is a San Diego based pharmaceutical company focused exclusively on developing drugs to combat emerging antibiotic resistance.

Dr Li, the Program Director of the project, said timing was critical as rising resistance to polymyxins would mean virtually a complete lack of treatment options for some life-threatening infections.

"It is not an exaggeration to state that the world is on the brink of a return to the pre-antibiotic era," Associate Professor Li said.

"In recent decades, bacteria that are resistant to all available antibiotics have emerged, while at the same time there has been a marked decline in the search for new drugs to combat these superbugs."

The five year project will design and develop new antibiotics to address bacterial resistance, and allow successful treatment of acute and chronic infections.

"We're aiming to develop at least one new drug candidate for future clinical trials," Associate Professor Li said.

Senior Vice-President for Research and Development and Chief Scientific Officer at Rempex Michael Dudley Pharm. D, said that industry-academic partnerships would be a very important mechanism for developing new antiinfectives for development.

“Rempex is looking forward to working with the MIPS team on identifying new drug candidates to meet the serious challenge of antibiotic resistance," Dr Dudley said.

The Infectious Diseases Society of America has identified a 'hit-list' of six multidrug-resistant bacteria as being the most difficult to treat. These bacteria will be targeted by the MIPS researchers and their Rempex collaborators in California.


Return to home

Post new comment

The content of this field is kept private and will not be shown publicly.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Allowed HTML tags: <a> <em> <strong> <cite> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Lines and paragraphs break automatically.

More information about formatting options

This question is for testing whether you are a genuine visitor, to prevent automated spam submissions.
Incorrect please try again
Enter the words above: Enter the numbers you hear:

Clinical Newsfeed

health news headlines provided courtesy of Medical News Today.

Click here to

Practice Development

Information Technology

Preventive Medicine

If any difficulty is found in subscribing, please use the "Contact Us" panel found in the navigation bar with the message "subscribe" and your email address.

Subscribe to our mailing list

* indicates required
Email Format

  • Copyright (C) 2000-2014 Computachem Services, All Rights Reserved.

Website by Ablecode